---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-26-000027"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T01:25:42.471895+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ligand terminates TR-Beta license with Viking over alleged material breach; Viking disputes

## Summary
- Termination of TR-Beta Program (including VK2809 and VK0214) effective May 4, 2026.
- Ligand asserts Viking materially breached obligation to use commercially reasonable efforts.
- Viking disputes termination; Ligand intends to vigorously enforce its termination rights.
- Upon termination, licenses revert to Ligand; Viking must grant non-exclusive worldwide royalty-bearing license at low single digits royalty rate.

## SEC filing metadata
- accession: 0000886163-26-000027
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616326000027/0000886163-26-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616326000027/lgnd-20260424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-26-000027
- JSON: https://secwatch.observer/filing/0000886163-26-000027.json
- Plain text: https://secwatch.observer/filing/0000886163-26-000027.txt

## Source-grounded claims
- claim_id: 8e5f93fc994c58b44fe13b61d08e7fd8e5dd727d
  claim: LIGAND PHARMACEUTICALS INC terminated Master License Agreement with Viking Therapeutics, Inc. (effective 2026-04-24).
  evidence_excerpt: On April 24, 2026, Ligand Pharmaceuticals Incorporated (the “Company”) delivered written notice to Viking Therapeutics, Inc. (“Viking”) of termination of the TR-Beta Program (the “Termination Notice”) under that certain Master License Agreement, dated May 21, 2014, by and among the Company, Metabasis Therapeutics, Inc. and Viking, as amended by the First Amendment dated September 6, 2014, the Second Amendment dated April 8, 2015, and the Waiver, Consent and Third Amendment dated March 21, 2016 (the “License Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/886163/000088616326000027/0000886163-26-000027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.